MARÍA NIEVES CABRERA MARTÍN-rekin lankidetzan egindako argitalpenak (12)

2024

  1. Plasma ctDNA Monitoring of a PTCH1-Mutant Metastatic Adult Medulloblastoma Showing a Durable Benefit With Vismodegib

    Oncologist, Vol. 29, Núm. 5, pp. 377-383

  2. Response to Yilmaz et al.

    Anti-Cancer Drugs

2023

  1. Durable complete remission with local therapies after neoadjuvant and adjuvant nivolumab in recurrent/metastatic head and neck cancer

    Anti-Cancer Drugs, Vol. 34, Núm. 5, pp. 695-698

  2. Safety and preliminary activity of pembrolizumab-carboplatin-paclitaxel in heavily pretreated and/or fragile patients with PDL1-positive recurrent/metastatic head and neck cancer

    Oncology Letters, Vol. 25, Núm. 1

2022

  1. Paclitaxel Plus Cetuximab as Induction Chemotherapy for Patients With Locoregionally Advanced Head and Neck Squamous Cell Carcinoma Unfit for Cisplatin-Based Chemotherapy

    Frontiers in Oncology, Vol. 12

2021

  1. Major and durable response to second-line pembrolizumab-carboplatin-paclitaxel in an oral cavity cancer patient

    Anti-Cancer Drugs, Vol. 32, Núm. 5, pp. 580-584

  2. Major pathological response and durable locoregional control after neoadjuvant pembrolizumab-carboplatin-paclitaxel in head and neck cancer

    Oral Oncology

  3. Safety and Efficacy of Cetuximab-Based Salvage Chemotherapy After Checkpoint Inhibitors in Head and Neck Cancer

    Oncologist, Vol. 26, Núm. 6, pp. e1018-e1035

  4. Tumor cerebral de alto grado versus accidente cerebrovascular. Utilidad del corregistro de PET y RM

    Anales de la Real Academia Nacional de Medicina, Núm. 138, pp. 176-179

2020

  1. Increased clinical and plasma EBV DNA responses to platinum-gemcitabine after nivolumab in patients with heavily platinum-pretreated nasopharyngeal cancer

    Oral Oncology

2019

  1. Durable intracranial and extracranial response to nivolumab with appearance of secondary resistance in a heavily pretreated patient with head and neck cancer

    Head and Neck, Vol. 41, Núm. 6, pp. E86-E92

  2. Response to immunotherapy rechallenge after interval chemotherapy in a patient with head and neck cancer

    Anti-Cancer Drugs, Vol. 30, Núm. 2, pp. 149-152